Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KEYNOTE-PNC-34

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

- PMLiVE

Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer

More than 72,680 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Merck and Exelixis partner to evaluate new cancer combination treatments

The companies will evaluate the regimens in head and neck cancer and renal cell carcinoma

- PMLiVE

Merck’s Keytruda shows promise as perioperative head and neck cancer treatment

More than 58,450 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Immutep’s LAG-3 immunotherapy candidate shows promise in head and neck cancer

Approximately 600,000 new cases of head and neck squamous cell carcinoma are diagnosed globally every year

- PMLiVE

AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab

The INTERLINK-1 study assessed the combination drug candidate to treat patients with head and neck cancer

- PMLiVE

Merck KGaA gains exclusive rights to Debiopharma’s late-stage oncology asset

Development and commercialisation deal could be worth up to $1.08bn

- PMLiVE

Immutep slumps on latest efti data in breast cancer

Drug was unable to improve progression-free survival compared to placebo

- PMLiVE

Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

Checkpoint inhibitor unlikely to improve progression-free survival

- PMLiVE

Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC

- PMLiVE

Norgine moves to raise awareness of head and neck cancer procedure

Partners with the Make Sense campaign on sentinel lymph node mapping work

AstraZeneca AZ

Trials of AZ’s durvalumab restart as FDA hold is relaxed

Bleeding side effects in two head and neck cancer studies not attributed to the PD-L1 inhibitor

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links